Co-principal investigators, Dr. James Baumgartner, MD and Pediatric Surgeon at Florida Hospital for Children, and Linda Baumgartner, Certified Auditory Verbal Therapist at Little HEARoes and Clarke Schools for Hearing and Speech, performed the study at the Florida Hospital for Children.
The study was published in August 2018 by the Journal of Audiology and Otology, and institutional funding was provided solely by CBR, a California Cryobank company.
As part of their commitment to help advance the science of newborn stem cells, CBR funded this phase 1 pilot study to assess the safety and preliminary efficacy of infusions of autologous umbilical cord blood in 11 children with acquired SNHL.
The study demonstrated that the cord blood infusions were safe, feasible, and well tolerated. In addition, 45% of participants showed improvements on Auditory Brainstem Response after their infusion.
SNHL is defined as hearing loss due to damage or dysfunction of the inner ear (as opposed to other structures of the ear).
This can be a result of premature birth, infections, or exposure to noise or ototoxic drugs, resulting in irreversible damage to the fragile hair cells (cilia) in the inner ear.
Although hearing aids or cochlear implants help to improve the ability to hear in individuals who have SNHL, these current interventions don't address the underlying cause. Currently, there is no cure for SNHL.
Founded in 1992, CBR is entrusted by parents with storing more than 800,000 children's cord blood and cord tissue samples. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial